Morphosys AG - MOR STOCK NEWS

IMPACT

SENTIMENT

11/20/2023 04:30 PM

MOR : Nasdaq

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

IMPACT

SENTIMENT

11/15/2023 04:01 PM

MOR : Nasdaq

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

IMPACT

SENTIMENT

11/09/2023 04:20 PM

MOR : Nasdaq MPSYF : OTC

Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

IMPACT

SENTIMENT

11/02/2023 09:45 AM

MOR : Nasdaq MPSYF : OTC

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

IMPACT

SENTIMENT

10/25/2023 05:10 AM

MOR : Nasdaq MPSYF : OTC

MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023

IMPACT

SENTIMENT

09/12/2023 04:20 PM

MOR : Nasdaq MPSYF : OTC

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

IMPACT

SENTIMENT

08/09/2023 04:01 PM

MOR : Nasdaq

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

IMPACT

SENTIMENT

05/03/2023 04:01 PM

MOR : Nasdaq

MorphoSys AG Reports First Quarter 2023 Financial Results

IMPACT

SENTIMENT

04/27/2023 04:20 PM

MOR : Nasdaq

Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023

IMPACT

SENTIMENT

04/16/2023 03:01 PM

INCY : Nasdaq MOR : Nasdaq

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

Morphosys AG

Nasdaq:MOR

MOR Rankings

#2884 Ranked by Market Cap

N/A Ranked by Dividends

MOR Stock Data

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

Country Germany

City Planegg

About MOR

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US.